J
Jennifer A. Woyach
Researcher at Ohio State University
Publications - 290
Citations - 11838
Jennifer A. Woyach is an academic researcher from Ohio State University. The author has contributed to research in topics: Ibrutinib & Chronic lymphocytic leukemia. The author has an hindex of 44, co-authored 217 publications receiving 8786 citations. Previous affiliations of Jennifer A. Woyach include James Cancer Hospital & The Ohio State University Wexner Medical Center.
Papers
More filters
Journal ArticleDOI
Resistance Mechanisms for the Bruton's Tyrosine Kinase Inhibitor Ibrutinib
Jennifer A. Woyach,Richard R. Furman,Ta-Ming Liu,Hatice Gulcin Ozer,Marc Zapatka,Amy S. Ruppert,Ling Xue,Daniel Hsieh Hsin Li,Susanne M. Steggerda,Matthias Versele,Sandeep S. Dave,Jenny Zhang,Ayse Selen Yilmaz,Samantha Jaglowski,Kristie A. Blum,Arletta Lozanski,Gerard Lozanski,Danelle F. James,Jacqueline C. Barrientos,Peter Lichter,Stephan Stilgenbauer,Joseph J. Buggy,Betty Y. Chang,Amy J. Johnson,John C. Byrd +24 more
TL;DR: Functional analysis showed that the C481S mutation of BTK results in a protein that is only reversibly inhibited by ibrutinib, which underscores the importance of the B-cell-receptor pathway in the mechanism of action of ibrUTinib in CLL.
Journal ArticleDOI
Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia
John C. Byrd,Bonnie K. Harrington,Susan O'Brien,Jeffrey A. Jones,Anna Schuh,S Devereux,Jorge M. Chaves,William G. Wierda,Farrukh T. Awan,Jennifer R. Brown,Peter Hillmen,Deborah M. Stephens,Paolo Ghia,Jacqueline C. Barrientos,John M. Pagel,Jennifer A. Woyach,Dave Johnson,Jane Huang,Xiaolin Wang,Allard Kaptein,Brian J. Lannutti,Todd Covey,Maria Fardis,Jesse McGreivy,Ahmed Hamdy,Wayne Rothbaum,Raquel Izumi,Thomas G. Diacovo,Amy J. Johnson,Richard R. Furman +29 more
TL;DR: In this study, the selective BTK inhibitor acalabrutinib had promising safety and efficacy profiles in patients with relapsed CLL, including those with chromosome 17p13.1 deletion.
Journal ArticleDOI
Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes.
Jason A. Dubovsky,Kyle A. Beckwith,Gayathri Natarajan,Jennifer A. Woyach,Samantha Jaglowski,Yiming Zhong,Joshua Hessler,Ta-Ming Liu,Betty Y. Chang,Karilyn Larkin,Matthew R. Stefanovski,Danielle L. Chappell,Frank Frissora,Lisa L. Smith,Kelly A. Smucker,Joseph M. Flynn,Jeffrey A. Jones,Leslie A. Andritsos,Kami J. Maddocks,Amy Lehman,Richard R. Furman,Jeff P. Sharman,Anjali Mishra,Michael A. Caligiuri,Abhay R. Satoskar,Joseph J. Buggy,Natarajan Muthusamy,Amy J. Johnson,John C. Byrd +28 more
TL;DR: Ibrutinib is established as a clinically relevant and physiologically potent ITK inhibitor with broad therapeutic utility and ITK as an irreversible T-cell target of ibrut inib.
Journal ArticleDOI
Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL
Jennifer A. Woyach,Amy S. Ruppert,Nyla A. Heerema,Weiqiang Zhao,Allison M Booth,Wei Ding,Nancy L. Bartlett,Danielle M. Brander,Paul M. Barr,Kerry A. Rogers,Sameer A. Parikh,Steven Coutre,Arti Hurria,Jennifer R. Brown,Gerard Lozanski,James S. Blachly,Hatice Gulcin Ozer,Brittny Major-Elechi,Briant Fruth,Sreenivasa Nattam,Richard A. Larson,Harry P. Erba,Mark R. Litzow,Carolyn Owen,Charles S. Kuzma,Jeremy S. Abramson,Richard F. Little,Scott E. Smith,Richard Stone,Sumithra J. Mandrekar,John C. Byrd +30 more
TL;DR: Among older patients with untreated CLL, treatment with ibrutinib was superior to treatment with bendamustine plus rituximab with regard to progression‐free survival, and there was no significant difference among the three treatment groups with respect to overall survival.
Journal ArticleDOI
Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia
Kami J. Maddocks,Amy S. Ruppert,Gerard Lozanski,Nyla A. Heerema,Weiqiang Zhao,Lynne V. Abruzzo,Arletta Lozanski,Melanie E. Davis,Amber Gordon,Lisa L. Smith,Rose Mantel,Jeffrey A. Jones,Joseph M. Flynn,Samantha Jaglowski,Leslie A. Andritsos,Farrukh T. Awan,Kristie A. Blum,Michael R. Grever,Amy J. Johnson,John C. Byrd,Jennifer A. Woyach +20 more
TL;DR: Sequencing data confirm initial reports associating mutations in BTK and PLCG2 with progression and clearly show that CLL progressions are associated with these mutations, while RT is likely not, and shows poor prognosis after discontinuation.